At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
BL-M17D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
In Brief
A Phase 1 clinical trial evaluating BL-M17D1 for Esophageal Cancer and 4 related conditions. Currently recruiting, targeting 20 participants across 1 site.
Detailed Summary
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 1Recruiting
20252026
First PostedJul 2024
Enrollment StartJul 2024
TodayJul 2026
Primary CompletionAug 2026
First PostedJul 15, 2024
Enrollment StartJul 24, 2024
Primary CompletionAug 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 2.0 years agoPrimary completion in 1 month
Interventions
BL-M17D1drug
Administration by intravenous infusion for a cycle of 3 weeks.